Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Accretive Health
So what: Revenue improved 30% this quarter, to $163.7 million, but fell just short of analyst estimates, which is weighing on shares. Profit was in line with expectations at $160,000, or $0.04 per share.
Now what: The earnings miss wasn't dramatic and the company reaffirmed full-year guidance in the range of $0.42 to $0.45. That's on the low end of estimates, but the 10% drop the stock is currently experiencing seems excessive. That said, I'm still not jumping into shares because the top end of guidance puts the stock at a hefty 58 P/E multiple for 2011 earnings.
Interested in more info on Accretive Health? Add it to your watchlist.